Previous 10 | Next 10 |
home / stock / gikly / gikly news
2023-11-29 08:21:29 ET More on Grifols Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript Grifols: Cheap For A Reason Historical earnings data for Grifols, S.A. Financial information for Grifols, S.A. Historical earnings data for Grifols, S.A. ...
2023-11-02 22:33:06 ET Grifols, S.A. (GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo -...
2023-07-27 15:45:16 ET Grifols, S.A. (GRFS) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Ca...
2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...
2023-05-09 22:36:06 ET Grifols, S.A. (GRFS) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participa...
2023-03-06 09:07:53 ET Grifols ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) said it entered a research, development and sublicense agreement with Selagine for developing and selling immunoglobulin eye drops for dry eye disease. Under the agreement, Selagine — ...
The following slide deck was published by Grifols, S.A. in conjunction with their 2022 Q4 earnings call. For further details see: Grifols, S.A. 2022 Q4 - Results - Earnings Call Presentation
Grifols, S.A. (GRFS) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Peter Verdult...
We are value investors. In constructing portfolios for our clients, we seek out companies that we believe are trading in the market at significant discounts to their underlying value. These businesses must offer significant profit potential and be run by managers who think and act as owne...
Grifols (NASDAQ:GRFS) unit Araclon Biotech reported results for the first part of a phase 2 trial of its vaccine ABvac40 for Alzheimer's Disease (AD) and data on two studies of its assay ABtest-MS to identify early-stage AD. The company said ABvac40 meets the main objectives on safe...
News, Short Squeeze, Breakout and More Instantly...
Grifols SA Barcelona ADR Company Name:
GIKLY Stock Symbol:
OTCMKTS Market:
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Grifols To Contact Him Directly To Discuss Their Options If you suffered significant losses in Grifols stock or options and would like to discuss your legal rights, call Faruqi & Faruq...
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma - The new Biomat USA plasma donor center, located at UMass Chan Medical School campus in Worcester, Mass., is Grifols' first donor center in the state and secon...